LabCorp Backs Resolution Bioscience’s Liquid Biopsy Test for NSCLC
XTalks
SEPTEMBER 28, 2020
The test is based on the detection of actionable genes – genes with known driver mutations that can be targeted by an approved therapy (or investigational therapies in clinical trials). Based on the genetic biomarker(s) identified, the most effective therapy targeting the specific molecular marker can be selected.
105 
Let's personalize your content